Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: Effects on motor function and quality of life in patients with parkinson's disease with end-of-dose wearing off

International Journal of Neuroscience

Volumn 121, Issue 11, 2011, Pages 605-613

  Lew, Mark F ^a   Somogyi, Monique ^b   McCague, Kevin ^b   Welsh, Mickie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dopamine fluctuations; End of dose wearing off; Levodopa carbidopa entacapone; Motor symptoms; Parkinson's disease; Quality of life

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA;

ABNORMAL URINE COMPOSITION; AGED; ARTICLE; CHROMATURIA; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSKINESIA; FATIGUE; FEMALE; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHYSICAL MOBILITY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TABLET; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SINGLE-BLIND METHOD;

EID: 80755159064     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.598982     Document Type: Article

References (42)

1. Boiko, A. N., Batysheva, T. T., Minaeva, N. G., Babina, L. A., Vdovichenko, T. V., Zhuravleva, E. Y., Shikhkerimov, R. K., Malykhina, E. A., Khozova, A. A., Zaitsev, K. A., & Kostenko, E. V. (2008). Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neuroscience and Behavioral Physiology, 38, 933-936.
2. Boomsma, F., Meerwaldt, J. D., Man in't Veld, A. J., Hovestadt, A., & Schalekamp, M. A. (1989). Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: Effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. Journal of Neurology, 236, 223-230. (Pubitemid 19144806)
3. Brooks, D. J., Agid, Y., Eggert, K., Widner, H., Ostergaard, K., Holopainen, A., & TC-INIT Study Group (2005). Treatment of end-of-dose wearing-off in parkinson's disease: Stalevo: Levodopa/carbidopa/entacapone and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. European Neurology, 53, 197-202. (Pubitemid 41404749)
4. Brooks, D. J., & Sagar, H. (2003). Entacapone is benefcial in both fuctuating and non-fuctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology Neurosurgery Psychiatry, 74, 1071-1079.
5. Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005). Impact of the motor complications of Parkinson's disease on the quality of life. Movement Disorder, 20, 224-230. (Pubitemid 40361128)
6. Durif, F., Devaux, I., Pere, J. J., Delumeau, J. C., Bourdeix, I., & F-01 Study Group (2001). Effcacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open, multicenter study. European Neurology, 45, 111-118. (Pubitemid 32215799)
7. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C. W., Tanner, C., Marek, K., & Parkinson Study Group (2004). Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine, 351, 2498-2508.
8. Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005). Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Movement Disorder, 20, 523-539. (Pubitemid 40862249)
9. Hauser, R. A. (2004). Levodopa/carbidopa/entacapone (Stalevo). Neurology, 62, S64-S71. (Pubitemid 38082854)
10. Heikkinen, H., Varhe, A., Laine, T., Puttonen, J., Kela, M., Kaakkola, S., & Reinikainen, K. (2002). Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. British Journal of Clinical Pharmacology, 54, 363-371. (Pubitemid 35334948)
11. Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age Ageing, 26, 353-357. (Pubitemid 27448379)
12. Jenner, P. (2003). The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism & Related Disorders, 9, 131-137. (Pubitemid 36173561)
13. Koller, W., Guarnieri, M., Hubble, J., Rabinowicz, A. L., & Silver, D. (2005). An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. Journal of Neural Transmission, 112, 221-230. (Pubitemid 40179116)
14. Larsen, J. P., Worm-Petersen, J., Sidén, A., Gordin, A., Reinikainen, K., Leinonen, M., & NOMESAFE Study Group (2003). The tolerability and effcacy of entacapone over 3 years in patients with Parkinson's disease. European Journal of Neurology. 10, 137-146. (Pubitemid 36308207)
15. Lyons, K. E., & Pahwa, R. (2006). Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. Clinical Neuropharmacology, 29, 73-76. (Pubitemid 44357155)
16. Miyasaki, J. M., Martin, W., Suchowersky, O., Weiner, W. J., & Lang, A. E. (2002). Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 58, 11-17. (Pubitemid 34041931)
17. Morgan, J. P., Bianchine, J. R., Spiegel, H. E., Rivera-Calimlim, L., & Hersey, R. M. (1971). Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fuorometric assays. Archives of Neurology, 25, 39-44.
18. M üller, T., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., Goetze, O., & Woitalla, D. (2006). Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. Journal of Neural Transmission, 113, 1441-1448 (Pubitemid 44435882)
19. Myllyla, V. V., Kultalahti, E. R., Haapaniemi, H., & Leinonen, M. (2001). Twelve-month safety of entacapone in patients with Parkinson's disease. European Journal of Neurology, 8, 53-60 (Pubitemid 32154574)
20. Myllylä, V. V., Sotaniemi, K. A., Illi, A., Suominen, K., & Keränen, T. (1993). Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. European Journal of Clinical Pharmacology, 45, 419-423. (Pubitemid 23361940)
21. Nutt, J. G., & Fellman, J. H. (1984). Pharmacokinetics of levodopa. Clinical Neuropharmacology, 7, 35-49. (Pubitemid 14138567)
22. Nutt, J. G., Woodward, W. R., Beckner, R. M., Stone, C. K., Berggren, K., Carter, J. H., Gancher, S. T., Hammerstad, J. P., & Gordin, A. (1994). Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology, 44, 913-919. (Pubitemid 24158809)
23. Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Te m ino, B., Mena-Segovia, J., Rodŕiguez, M., & Olanow, C. W. (2008). The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Annals of Neurology, 64, S30-S46.
24. Olanow, C. W., Kieburtz, K., Stern, M., Watts, R., Langston, J. W., Guarnieri, M., Hubble, J., & US01 Study Team (2004). Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Archives of Neurology, 61, 1563-1568. (Pubitemid 39350267)
25. Olanow, C. W., & Obeso, J. A. (2000). Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: Implications for the early use of COMT inhibitors. Neurology, 55, S72-S77; discussion S8-81.
26. Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006a). Continuous dopamine-receptor treatment of Parkinson's disease: Scientifc rationale and clinical implications. Lancet Neurology, 5, 677-687. (Pubitemid 44081890)
27. Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006b). Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clinical Practice, 2, 382-392. (Pubitemid 43983776)
28. Onofrj, M., Thomas, A., Vingerhoets, F., Martin, W., Giménez- Roldán, S., Azulay, J. P., Bernhard, G., Schmidt, W., & Markabi, S. (2004). Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: Results of a large multicentre open-label study. Journal of Neural Transmission, 111, 1053-1063. (Pubitemid 39037126)
29. Parkinson Study Group. (1997). Entacapone improves motor fuctuations in levodopa-treated Parkinson's disease patients. Annals of Neurology, 42, 747-755.
30. Poewe, W. H., Deuschl, G., Gordin, A., Kultalahti, E. R., Leinonen, M., & Celomen Study Group (2002). Effcacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurologica Scandinavica, 105, 245-255. (Pubitemid 34407226)
31. Rao, S. S., Hofmann, L. A., & Shakil, A. (2006). Parkinson's disease: diagnosis and treatment. American Family Physician, 74, 2046-2054.
32. Rinne, U. K., Larsen, J. P., Siden, A., Worm-Petersen, J., & Nomecomt Study Group. (1998). Entacapone enhances the response to levodopa in parkinsonian patients with motor fuctuations. Neurology, 51, 1309-1314. (Pubitemid 28520549)
33. Ruottinen, H. M., & Rinne, U. K. (1996a). A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clinical Neuropharmacology, 19, 283-296. (Pubitemid 26250111)
34. Ruottinen, H. M., & Rinne, U. K. (1996b). Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fuctuations. Journal of Neurology Neurosurgery Psychiatry, 60, 36-40. (Pubitemid 26012264)
35. Schapira, A. H., Emre, M., Jenner, P., & Poewe, W. (2009). Levodopa in the treatment of Parkinson's disease. European Journal of Neurology, 16, 982-989.
36. Silver, D. E. (2004). Clinical experience with the novel levodopa formulation entacapone + levodopa +carbidopa (Stalevo). Expert Review of Neurotherapeutics, 4, 589-599. (Pubitemid 38890587)
37. Smith, L. A., Jackson, M. J., Al-Barghouthy, G., Rose, S., Kuoppamaki, M., Olanow, W., & Jenner, P. (2005). Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Movement Disorder, 20, 306-314. (Pubitemid 40613291)
38. Stacy, M. (2009). Medical treatment of Parkinson disease. Neurologic Clinic, 27, 605-631.
39. Stalevo® [prescribing information].(2009). East Hanover, NJ: Novartis Pharmaceuticals Corporation.
40. Waters, C. H. (1997). Managing the late complications of Parkinson's disease. Neurology, 49, S49-S57. (Pubitemid 27304771)
41. Weiner, W. J. (2006). Motor fuctuations in Parkinson's disease. Reviews in Neurological Diseases, 3, 101-108.
42. Welsh, M., McDermott, M. P., Holloway, R. G., Plumb, S., Pfeiffer, R., Hubble, J., & Parkinson Study Group. (2003). Development and testing of the Parkinson's disease quality of life scale. Movement Disorder, 18, 637-645. (Pubitemid 36790278)